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Hypomyelinating Leukodystrophies:
Translational Research Progress and
Prospects
Petra J. W. Pouwels, PhD,1 Adeline Vanderver, MD,2
Genevieve Bernard, MD, MSc, FRCPC,3 Nicole I. Wolf, MD, PhD,4
Steffi F. Dreha-Kulczewksi, MD,5 Sean C. L. Deoni, PhD,6 Enrico Bertini, MD, PhD,7
Alfried Kohlsch€utter, MD,8 William Richardson, FMedSci, FRS,9
Charles ffrench-Constant, PhD,9 Wolfgang K€ohler, MD,10 David Rowitch, MD, PhD,11
and A. James Barkovich, MD12,13
Hypomyelinating leukodystrophies represent a genetically heterogeneous but clinically overlapping group of herit-
able disorders. Current management approaches in the care of the patient with a hypomyelinating leukodystrophy
include use of serial magnetic resonance imaging (MRI) to establish and monitor hypomyelination, molecular diagnos-
tics to determine a specific etiology, and equally importantly, careful attention to neurologic complications over
time. Emerging research in oligodendrocyte biology and neuroradiology with bedside applications may result in the
possibility of clinical trials in the near term, yet there are significant gaps in knowledge in disease classification, char-
acterization, and outcome measures in this group of disorders. Here we review the biological background of myelina-
tion, the clinical and genetic variability in hypomyelinating leukodystrophies, and the insights that can be obtained
from current MRI techniques. In addition, we discuss ongoing research approaches to define potential outcome
markers for future clinical trials.
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The concept of hypomyelinating disorders was origi-nated by Schiffmann, van der Knaap, and col-
leagues.1–3 Among the inherited white matter (WM)
disorders, hypomyelinating leukodystrophies (HLDs) are
notable for abnormalities in myelin development rather
than destruction. This class of disorders is distinguished
by their characteristic appearance on magnetic resonance
imaging (MRI), namely, lessening or absence of the T2
hypointensity that typically signifies the presence of mye-
lin, often without the significant lessening of T1 hyperin-
tensity seen in the other, nonhypomyelinating
leukodystrophies. Other MRI features help to narrow the
differential diagnosis and focus genetic and metabolic
testing.3
We are entering a phase of clinical research for
HLDs where identification of outcome measures of
potential treatment benefit is crucial. In ultrarare dis-
eases, clinical features, and natural history are often
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poorly known; therefore, clinical/neurological parameters
alone are insufficient as endpoints for clinical efficacy
studies. In this case, another possible acceptable clinical
trial design includes the use of biomarkers as surrogate
endpoints. The adoption of criteria for biomarkers of
efficacy is an important feasibility step for the planning
and execution of clinical studies because it provides an
objective endpoint at a defined period of time after an
intervention has been initiated. Proposing a standard
measure of myelination based upon magnetic resonance
(MR) metrics as a reliable biomarker could therefore
greatly encourage clinical research.
With these challenges in mind, we organized a
multidisciplinary group to address clinical and future
research priorities for HLDs. The group makes consensus
recommendations for MRI and neurological assessments
in clinical care, endpoints for clinical research, and
potential methods to detect myelin in the human brain
with greater specificity and sensitivity.
Biological Basis of Myelination and HLDs
Oligodendrocytes are the myelinating cells of the central
nervous system (CNS; Fig 1). Myelin enables rapid trans-
mission of action potentials through saltatory conduc-
tion,4,5 provides trophic support and protection for
axons,6–8 and allows for packing of greater axon densities
during the evolution of brain complexity.9 Almost half of
the human brain is comprised of tracts of myelinated
axons in WM, and it is therefore not surprising that leu-
kodystrophies, caused by deficient deposition or destruc-
tion of myelin, have significant functional effects.
Myelination is an energy-expensive process, as
developing oligodendrocyte precursor cells (OPCs)
undergo as much as a 6,500-fold increase in membrane
surface area as they differentiate into oligodendrocytes
that provide up to 100 myelin segments on multiple
axons through extension of protoplasmic processes.10,11
Mature oligodendrocytes also provide ongoing trophic
support to axons, in part through functions of the
FIGURE 1: Overview of oligodendrocyte lineage development. Oligodendrocyte development commences in the midgestation
mammalian embryo. Multipotent neural progenitor cells competent to produce oligodendrocytes express the transcription fac-
tor OLIG2, and cell intrinsic and environmental interactions with other transcription factors (eg, SOX10, NKX2.2) lead to speci-
fication of oligodendrocyte precursor cells (OPCs) marked by expression of platelet-derived growth factor receptor-a (PDGFRa)
and neuron-glial antigen 2 (NG2). Such OPCs proliferate after specification, migrate throughout the central nervous system
parenchyma, and differentiate under control of myelin regulatory factor (MRF) and other intrinsic programs. In white matter,
premyelinating oligodendrocytes engage with axons, and it is thought that physical and activity-dependent cues trigger myelin
wrapping, marked initially by transition from O41 to O11 stages, and eventually expression of proteolipid protein 1 (PLP1)
and other mature markers. One oligodendrocyte can provide hundreds of myelin segments to adjacent axons. Myelination ena-
bles formation of nodes of Ranvier, which cluster sodium channels for saltatory conduction. Myelination is also thought to sta-
bilize axonal membranes, which results in physical properties detectable by magnetic resonance imaging. Transcription factors
are indicated by unfilled boxes and cellular markers by violet/filled boxes.
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monocarboxylate transporter 1.12,13 Finally, initiation of
myelination and myelin maintenance is regulated by the
availability of glycolytic and lipid substrates such as
purines, glucose, and lactate.6,14 OPCs are widespread in
the normal adult CNS, where they contribute to myelin
repair (eg, in multiple sclerosis15) and turnover of myelin
within normal WM.16
The focus of this review will be the HLDs. As
shown in Figure 1, early oligodendrocyte development
comes under control by specific transcription factors that
promote glial subtype specification of OPCs. Transcrip-
tion factors Olig2, Sox10, and Nkx2.2 are essential for
early stages of OPC development, whereas other tran-
scriptional proteins, including myelin regulatory factor
(MyRF), as well as chromatin remodeling and signaling
pathways such as integrin and PI3 kinase, coordinate to
promote later stages of oligodendrocyte differentiation
and myelin remodeling.17,18 No HLD-causing mutations
have been identified in these pathways, perhaps because
they are essential in many cell types. The sheath then
formed is enriched in myelin-specific lipids and proteins
including proteolipid protein 1 (PLP1). Mutations in
PLP1 are known to be causative of Pelizaeus–Merzbacher
disease (PMD), a classic example of an HLD. Different
types of mutations in PLP1 may have different impacts
on the oligodendrocyte lineage. The most common alter-
ation is duplication of the entire gene, suggesting that
gene dosage is essential. Severe missense mutations in
PLP1 trigger the unfolded protein response and cell
death of OPCs, preventing myelination, leading to the
severe connatal form of the disease.19 Milder missense
mutations and null mutations are associated with milder
forms. Although OPCs likely respond to the loss of mye-
lin in HLDs, their intrinsic mutation likely renders them
ineffective in repair.
Diagnosis and Management of HLDs
HLDs are characterized by a paucity of myelin develop-
ment based on histochemistry and MRI criteria. MRI
typically shows variable signal (ie, hyper-, hypo-, or iso-
intense) on T1-weighted imaging and mild hyperintensity
on T2-weighted imaging of the WM compared to gray
matter (GM) signal (Fig 2A–F).2 This is distinct
from other leukodystrophies, in which more hypointense
FIGURE 2: Magnetic resonance imaging (MRI) of hypomyeli-
nating leukodystrophy patients in comparison to subjects
with normal MRI. (A–C) Sagittal T1-weighted images show
hypointense signal of corpus callosum in (A) a 4-year-old
Pelizaeus–Merzbacher disease (PMD) patient and (B) additional
cerebellar atrophy in a 2-year-old hypomyelination, hypo-
dontia, and hypogonadotropic hypogonadism (4H) patient,
in comparison to (C) a 5-year-old control subject. (D–F) Axial
T2-weighted images show homogeneous T2 hyperintensity
of white matter in (D) a 4-year-old PMD patient and similar
white matter hyperintensity in addition to hypointensity of
the globi pallidi and lateral thalami in (E) a 2-year-old 4H
patient in comparison to (F) a 5-year-old control subject. (G,
H) Magnetic resonance spectrum of white matter in (G) a
17-year-old 4H patient shows reduced choline (Cho) in com-
parison to (H) a 5-year-old control subject. (I, J) Magnetiza-
tion transfer (MT) ratio maps and (K, L) MT saturation maps
show severe global reduction of MT values (manifested as
decreased hyperintensity) in (I, K) a 6-year-old 4H patient
compared to (J, L) a 6-year-old control subject. (M, N) Frac-
tional anisotropy (FA) maps and (O, P) radial diffusivity (RD)
maps show a reduction of FA (manifested as decreased
white matter hyperintensity in M compared with N) and an
increase of RD (manifested as less white matter hypointen-
sity in O compared with P) in a 4-year-old 4H patient (M, O)
in comparison to a 7-year-old control subject (N, P). The
images of each pair I-J, K-L, M-N, and O-P are shown at the
same intensity scale. Cr5 creatine; Ins5 inositol; NAA5N-
acetylaspartate.
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T1-weighted and more severely hyperintense T2-weighted
WM imaging signals are seen, usually in a more geo-
graphic or localized distribution.
It is also important to differentiate HLDs from
neuronal diseases with secondary hypomyelination, which
carry an independent differential diagnosis, such as
AGC1-,20,21 HSPD1-,22 and AIMP1-related disor-
ders.23,24 Neuronal diseases with secondary hypomyelina-
tion have prominent GM symptoms, such as early onset
epilepsy and severe intellectual disability. They com-
monly present with microcephaly and/or early and severe
cerebral atrophy. It is also important to differentiate
HLDs from delayed myelination. When a lack of myelin
deposition is noticed on an MRI in a child younger than
2 years, a second MRI should be performed at least 6
months later to assess for significantly improved myelina-
tion, diagnostic of delayed myelination (in distinction,
increase in myelination is not observed in HLDs).
HLDs are genetically and clinically diverse (Table
1), but have commonalities as a group. Most HLD
patients present in the neonatal or infantile period with
axial hypotonia, which evolves to spastic quadriparesis,
and have or will develop nystagmus. Patients with PMD,
Pelizaeus-Merzbacher–like disease caused by mutations in
GJC2,25 and SOX10-related disorders26 have early onset
of congenital nystagmus, whereas patients with hypomye-
lination, hypodontia, and hypogonadotropic hypogonad-
ism (4H),27,28 oculodentodigital dysplasia, and 18q-
syndrome develop nystagmus later in the course of their
disease or never. Cerebellar signs are often present and
can be the predominant clinical manifestation, such as in
4H, a RNA polymerase III–related leukodystrophy.
Extrapyramidal signs are not uncommon, especially dys-
tonia, but typically occur later in the disease course, with
the exception of hypomyelination with atrophy of the
basal ganglia and cerebellum (H-ABC), where dystonia is
often seen early in the disease. Cognitive function is rela-
tively preserved in most patients but typically declines
slowly or relatively late in the disease course. Another
possible neurological manifestation of HLDs is the pres-
ence of a peripheral neuropathy, which can be seen
inconsistently with PLP-null syndrome (one of the
TABLE 1. Hypomyelinating Leukodystrophies, Their Inheritance, and Their Respective Genetic Cause, When
Known
Hypomyelinating Disorder OMIM
Number
Abbreviation Inheritance Gene
18q- syndrome 601808 Sporadic 18q-
Cockayne syndrome 216400 AR ERCC6, ERCC8
Hypomyelination with atrophy
of the basal ganglia and cerebellum
612438 H-ABC Sporadic TUBB4A
Hypomyelination with congenital cataracts 610532 HCC AR FAM126A
Hypomyelination of early myelinated structures HEMS X-linked unknown
Hypomyelination with brainstem and
spinal cord involvement and leg spasticity
615281 HBSL AR DARS
Free sialic acid storage disease 604369 AR SLC17A5
Fucosidosis 230000 AR FUCA1
Pelizaeus–Merzbacher disease 312920 PMD X-linked PLP1
Pelizaeus-Merzbacher–like disease 608804 PMLD AR GJC2
Pol III-related leukodystrophies/4H 607694,
614381
4H AR POLR3A, POLR3B
Oculodentodigital dysplasia 164200 ODDD AD, sporadic GJA1
RARS-associated hypomyelination,
SOX10-associated disorders
609136 AR, AD,
sporadic
RARS, SOX10
Trichothiodystrophy with
hypersensitivity to sunlight
601675 AR ERCC2, ERCC3,
GTF2H5, MPLKIP
4H5 hypomyelination, hypodontia, and hypogonadotropic hypogonadism; AD5 autosomal dominant; AR5 autosomal recessive;
OMIM5Online Mendelian Inheritance in Man database.
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milder PMD forms), Cockayne syndrome, SOX10-related
disorders, and hypomyelination with congenital cataracts
(HCC). A full description of these conditions and the
reasons they are included within the HLDs is beyond the
scope of this review and described elsewhere.29
Some HLDs can present with an adult onset heredi-
tary spastic paraparesis phenotype. In addition to progres-
sive spastic paraplegia, dysarthria, dysphagia, and later
cognitive decline are frequent in adulthood. The late onset
HLD phenotypes have much milder MRI WM abnormal-
ities. In 4H, some affected patients present in late adoles-
cence or early adulthood with hypomyelination on MRI
that is not well correlated with the disease severity. A late
presentation is often associated with milder clinical symp-
toms and slower deterioration. A spectrum with more
severe infantile onset cases on one end and milder adoles-
cent or adult onset variants at the other extreme will
probably be part of most if not all HLDs.
In the diagnosis of a HLD, MRI pattern recogni-
tion is very useful (Table 2),3 but non-neurological
features, when present, can help the clinician in suspect-
ing one disorder versus another (Table 3). For example,
hypodontia and delayed puberty point to 4H, whereas
the presence of cataracts suggests HCC. Overall, it is
important to note that these systemic manifestations are
inconstant and may not be present in all affected
individuals.
Molecular diagnosis has become the mainstay in
diagnosis of hypomyelinating conditions, and a targeted
number of genes specific to hypomyelination should be
tested. A definitive molecular diagnosis will aid the clini-
cian with management, prognosis, and genetic
counseling.
Management of patients with HLDs will largely
depend on the specific diagnosis and individual severity
of the disease. Typical complications in patients with the
classic form of PMD include severe spasticity necessitat-
ing oral or intrathecal treatment with baclofen, chemode-
nervation, or selective dorsal rhizotomy. Dystonia is seen
more frequently in certain HLDs such as H-ABC and
TABLE 2. MRI Characteristics and the Diagnoses They Suggest
MRI Characteristic Suggests
Diffuse and homogeneous hypomyelination PMD
Diffuse and homogeneous hypomyelination with
hypomyelination of the brainstem, especially the pons
PMLD
Hypomyelination with areas of increased
T2 signal and decreased T1 signal
HCC, 18q- syndrome, HBSL
Relative T2 hypointensity of the dentate nuclei,
optic radiation, globi pallidi, anterolateral nuclei
of the thalami, corticospinal tract at the
level of the PLIC
Pol III/4H
Hypomyelination of early myelinating structures HEMS
Calcifications Cockayne syndrome, AGSa
Thin corpus callosum Pol III/4H, fucosidosis, Cockayne syndrome,
sialic acid storage disease
Cerebellar atrophy Pol III/4H, sialic acid storage disease, H-ABC,
ODDD, Cockayne syndrome, fucosidosis,
18q- syndrome (hypoplasia)
Basal ganglia abnormalities Atrophy (especially putamen), H-ABC; hyper T1
and hypo T2 of GP, fucosidosis; hypo T2 of GP,
Pol III/4H, ODDD
Prominent cerebral atrophy Infantile sialic acid storage disease, AGSa
4H5 hypomyelination, hypodontia, and hypogonadotropic hypogonadism; AGS5Aicardi–Goutie`res syndrome; GP5 globus pal-
lidus; H-ABC5 hypomyelination with atrophy of the basal ganglia and the cerebellum; HBSL5 hypomyelination with brainstem
and spinal cord involvement and leg spasticity; HCC5 hypomyelination with congenital cataracts; HEMS5 hypomyelination of
early myelinating structures; hyper5 hyperintensity; hypo5 hypointensity; MRI5magnetic resonance imaging; ODD-
D5 oculodentodigital dysplasia; PLIC5 posterior limb of the internal capsule; PMD5 Pelizaeus–Merzbacher disease;
PMLD5PMD-like; Pol III5 Pol III–related leukodystrophies.
aAGS may present with a hypomyelinating pattern on MRI.
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4H, and should be managed with appropriate pharmaco-
therapy. Scoliosis and hip dislocations are frequent com-
plications, and should be carefully prevented and treated
in a timely manner. Swallowing difficulties are present
early in severe forms, and in milder forms develop over
time. Epilepsy is an infrequent complication of HLDs. If
present, appropriate treatment with antiepileptic drugs
should be initiated. Specific complications of certain enti-
ties among the HLDs include endocrine abnormalities
(hypogonadotropic hypogonadism and, less frequently,
growth hormone deficiency) in 4H. Endocrine monitor-
ing should be done regularly; treatment decisions should
be made on an individual basis. Management of the den-
tal anomalies in 4H includes prosthetic treatment and
early detection of cavities.
Myelin Assessment by MRI
In addition to conventional T1- and T2-weighted imag-
ing, several advanced MRI techniques might be more
appropriate to clinically detect myelin in the human
brain. In the following sections, we discuss proton mag-
netic resonance spectroscopy (MRS), quantitative T1 and
T2, magnetization transfer imaging (MTI), and diffusion
tensor imaging (DTI).
Myelin Assessment by Proton MRS
Proton MRS allows separation of protons in different
chemical environments based upon the effects of sur-
rounding electron clouds upon the net strength of the
magnetic field felt by the proton (chemical shift) and the
influences of neighboring nuclei (spin–spin coupling).
Used for decades in analytical chemistry, it has been
applied to human diseases as a part of the MRI examina-
tion. Recently, MRS has been investigated as a tool in
the assessment of metabolic disorders and specifically
HLDs.30–32 However, the spectrum of myelin itself is
quite complex, essentially composed of overlapping spec-
tra of the many functional groups that are part of the
proteins and complex molecules that are components of
myelin.33 The peaks from most of the protons within
these functional groups are split (into doublets, triplets,
quadruplets, and more) by adjacent protons and/or have
T2 relaxation times too short to be apparent on in vivo
proton spectra.34 Therefore, the use of in vivo proton
MRS in patients with disorders of myelin formation is
mainly limited to assessment of the major peaks seen in
the human brain: choline, creatine, myo-inositol, gluta-
mate, glutamine, and N-acetylaspartate (NAA; see Fig
2G, H). None of these peaks has been shown to directly
reflect the presence or quantity of myelin in the
TABLE 3. Useful Non-Neurological Clinical Features to Orient the Diagnosis in Hypomyelinating
Leukodystrophies
Clinical Characteristics Suggests
Dysmorphic signs 18q- syndrome
Facial coarsening Sialic acid storage disease, fucosidosis
Cataracts HCC, Cockayne syndrome, Pol III/4H (rarely)
Myopia, typically
progressive and severe
Pol III/4H
Hearing loss Cockayne syndrome, SOX-10
Dental abnormalities Pol III/4Ha; Cockayne syndrome, propensity to cavities;
ODDD, enamel hypoplasia
Skin abnormalities Cockayne syndrome, hypersensitivity to sunlight; fucosidosis,
angiokeratoma corporis diffusum
Hand and feet abnormalities ODDD
Cardiac abnormalities 18q- syndrome; fucosidosis, cardiomegaly
Hepatosplenomegaly Sialic acid storage disease, fucosidosis
Endocrine abnormalities 18q- syndrome, Pol III/4H (delayed or absent puberty)
aThe dental abnormalities encountered in Pol III–related leukodystrophies are not universal and are highly variable: oligodontia,
hypodontia, delayed teeth eruption, abnormal sequence of teeth eruption, and abnormal color or shape of sometimes 1 but typi-
cally several teeth.
4H5 hypomyelination, hypodontia, and hypogonadotropic hypogonadism; HCC5 hypomyelination with congenital cataracts;
ODDD5 oculodentodigital dysplasia; Pol III5 Pol III–related leukodystrophies.
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developing brain, although combinations of peak heights
can be used to roughly monitor normal brain develop-
ment.35–37
Some authors have studied proton MRS in HLDs
and compared them with other leukodystrophies.38 They
found high creatine and myo-inositol levels and low
choline levels compared to controls.38 Takanashi et al
have studied the use of proton MRS in 2 mouse models
of HLDs, the msd mouse (a model of connatal PMD)31
and the shiverer (Shi) mouse (deficient for myelin basic
protein),39 and found very different proton MRS pat-
terns. NAA, which is normally metabolized to acetate
and aspartate in oligodendrocytes,40 is elevated in the
classic form of PMD.30,32 The most likely reason for this
is that the PLP1 proteins in PMD patients are abnor-
mally folded and accumulated in the endoplasmic reticu-
lum, resulting in the activation of an unfolded protein
response that finally leads to oligodendrocyte apoptotic
death before normal myelination occurs, leading to
higher NAA levels.41 In contrast, NAA is low in Shi
mice, presumably because the number of cortical neurons
is decreased39 for reasons that are not currently under-
stood. Choline may be reduced in HLDs, as cultured oli-
godendrocytes have a higher concentration of choline
than neurons, astrocytes, or oligodendrocyte precursors.42
However, at this time, it does not seem that MRS will be
useful by itself to quantify myelination.
Myelin Assessment by Quantitative T1 and T2
Much of the exquisite soft tissue contrast we have come
to expect from MRI arises from differences in the intrin-
sic T1 and T2 relaxation properties. In their most basic
description, both T1 and T2 relaxation processes result
from molecular motion and interactions, which are influ-
enced by the biophysical structure and biochemical envi-
ronment.43 In particular, characteristics such as density
(ie, water content/mobility); macromolecule, protein, and
lipid composition; and paramagnetic atom (eg, iron)
concentrations alter the local tissue environment, and
consequently affect tissue T1 and T2. In WM, for exam-
ple, the phospholipid-rich myelin sheath and associated
proteins, cholesterol, iron-containing oligodendrocytes
and glial cells, and reduced free water content all result
in decreased T1 and T2 relative to GM.
44 These relaxa-
tion time differences are readily apparent in the GM/
WM contrast in conventional T1- and T2-weighted
images of adult brain, and onset or alteration of this con-
trast has been used as a qualitative measure of myelin
changes. For example, the emergence of GM/WM con-
trast in the developing brain, associated with drastic
reductions in the T1 and T2 relaxation times, broadly
parallels the histological timeline of myelination.35 Simi-
larly, a change of contrast driven by prolonged T1 and
T2 in WM disorders, such as multiple sclerosis, can pri-
marily reflect focal myelin loss.45
Relaxation properties are extremely sensitive to local
microstructural and biochemical changes in WM, but
they are nonspecific and can reflect developing myelina-
tion, differing concentrations of iron (ferritin),46 water
content changes associated with fiber density and diame-
ter, or pathological processes such as edema and inflam-
mation.47 In an effort to improve myelin sensitivity and
specificity, a multiple-component approach has been pro-
posed.48–50 Here, the T1 and/or T2 signal curves
observed within an imaging voxel are assumed to be a
composite mixture from multiple distinct microanatomi-
cal tissue environments that, through their unique micro-
structure and biochemistry, have differing T1 and T2
characteristics and thus distinct MRI signal signatures
(Fig 3A, B). The aim of multiple component relaxation
analysis is to decompose and quantify these individual
FIGURE 3: Background of myelin water fraction determination. (A) Because of more interactions with surrounding molecules
and electrical/magnetic variations, myelin water has shorter relaxation times (T1,m and T2,m) than intra-/extracellular water (T1,w
and T2,w). (B) The signal intensity per voxel is a combination of myelin water and intra-/extracellular water, as shown here for
T1-weighted spoiled gradient recalled (SPGR) as a function of flip angle. (C) Additional T1/T2-weighted sequences allow for the
estimation of a myelin water fraction map.62
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signatures, allowing more direct assessment of myelin
content. Conventionally, this has been accomplished
through the acquisition of multiple32–48 spin-echo T2
decay data spanning a wide range of echo times (up to
320 milliseconds).51 Assuming a slow exchange regime
with respect to T2,
52 a non-negative least squares
approach is used to fit a semicontinuous log T2 distribu-
tion to the sampled decay data.51 Results of this fitting
have consistently revealed a bi- or trimodal T2 profile,
with a short T2 peak (T2< 30 milliseconds), moderate
T2 peak (60<T2< 150 milliseconds), and a long T2
peak (T2> 2 seconds).
52 Through imaging–histology
comparisons53,54 and in vivo studies of demyelinating
disorders,55 these peaks have been ascribed to 3 layers:
water trapped between the lipid myelin bilayers; the less
restricted intra- and extracellular water; and cerebrospinal
fluid, respectively.51,52 The volume ratio of the short T2
peak to the total area under the T2 distribution, termed
the myelin water fraction (MWF), has strong correlation
with histological assessments of myelin content,51,52 irre-
spective of inflammation or changes in water content.56
Recently, similar multicomponent T1 relaxation has been
demonstrated at ultrahigh field strengths.57 Thus, MWF
has the potential to be a better quantitative marker of
myelin than measures derived from MTI or DTI.58,59
However, MWF has not yet gained entrance into routine
clinical MRI because of limited spatial coverage, time
requirements, and frequent technical difficulties that
result in stimulated echo artifacts.
Due to the lengthy acquisition times required,
recent work has centered on the development of
3-dimensional multicomponent relaxation approaches,
such as rapid spiral imaging,60 or alternative non–spin
echo based imaging methodologies (ie, GRASE61 or
mcDESPOT62). These newer methods have the potential
to overcome some of the difficulties in integrating MWF
into standard clinical protocols (see Fig 3C), but need
further validation.63 They have already provided prelimi-
nary new insight into brain development and myelina-
tion,64 as well as myelin changes that reflect disease
course and severity in other WM disorders.65,66
Myelin Assessment by MTI
MTI targets magnetization exchange between immobile
macromolecular protons (bound pool), such as those
bound in proteins and lipid bilayers of myelin, and free
water protons (free pool). Magnetization transfer (MT) is
evoked by selectively saturating the bound pool with an
off-resonance radiofrequency pulse. This saturation is
then transferred to the free pool and observed as an
attenuation of the MR signal.67 In WM the MT effect is
overproportionately determined by MWF,68 suggesting
that MT characteristics mainly relate to myelin.
Quantitative MT methods adopt complex modeling
of the 2 pools, allowing mapping of multiple parameters
with the bound pool fraction f being most relevant.69,70
The bound pool is about 2 to 33 larger in WM (11%)
than in GM (4%), small in blood (2%), and absent in
cerebrospinal fluid.71 In demyelination, strong correla-
tions of f and magnetization transfer ratio (MTR) with
histologically quantified myelin density have been
detected in animal models72,73 and in human postmor-
tem multiple sclerosis studies.74,75 However, bovine brain
imaging and imaging–histology correlations have sug-
gested that nonmyelin WM, containing macromolecules
such as axonal membranes and glial cells, also modulate
MT measures.75–77 Moreover, general WM pathological
changes in demyelinating diseases have been shown to
influence and complicate MTmeasures of myelin.74,76,78
The utility of quantitative MT (qMT) parameters
has benefited greatly from studies in hypomyelinating
conditions such as those in shaking (Sh) pups, a canine
model with a PLP gene mutation,79 with f being most
discriminative. Because axons are preserved in Sh pups,
the results indicate a high correlation to normal myelina-
tion. Similar results have been obtained with qMT in
hypomyelinating Shi mice.80,81
Not surprisingly, MTR has been found significantly
decreased in childhood HLDs.38 MT saturation maps in
various HLDs in children revealed an overall decrease
with distinct spatial distributions of higher MT saturation
values, reflecting lack of myelin, and characteristic
regions containing more myelin in accordance with histo-
pathological findings (see Fig 2I–L).82 The sensitivity to
changes in myelination has rendered MT saturation a
suitable parameter to monitor treatment effects, as dem-
onstrated in cerebral folate transporter a deficiency with
hypomyelination. In preliminary studies, folinic acid
treatment may improve/normalize MT saturation values
(Dreha-Kulaczewski, unpublished observations).
Myelin Assessment by DTI
DTI can be used to assess the magnitude and direction
of water motion in a volume of tissue. If small volumes
are imaged at high resolution, this technique gives insight
into the microstructure of WM. Parallel myelinated
axons give rise to a high fractional anisotropy (FA), indi-
cating the direction of overall motion of water molecules
in the sampled voxel. In WM, this direction is deter-
mined by the largest eigenvalue of the diffusion tensor,
representing diffusivity parallel to the axons (axial diffu-
sivity [AD]), and by the 2 lower eigenvalues, representing
diffusivity perpendicular to the axons (radial diffusivity
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[RD]).83 RD has been interpreted as an indicator of
myelin density, based on increased values in mouse mod-
els of hypomyelination, the Shi mouse,84 the transgenic
hcv1-tk mouse,85 and the fixed brains of Plp1-transgenic
mice.86 AD has been interpreted as a measure of axonal
integrity; it is normal in Shi mice with relatively intact
axons, and decreased in hcv1-tk mice with reduced axonal
caliber.84,85 The increased RD in poorly myelinated WM
has been confirmed in the Sh pup; of all investigated
DTI parameters, the relative increase of RD was most
prominent, whereas the increase of AD was much
smaller, in accordance with paucity of myelin being the
most apparent histopathological observation.87 However,
the actual quantification of myelin by means of these
parameters has not yet been demonstrated.
It should be noted that the tensor model, although
widely used, is limited by the assumption of a Gaussian
distribution of water diffusion, and DTI parameters are
sensitive to partial volume averaging, because the size of
the voxels being assessed is much larger than that of the
crossing fiber tracts.88 To overcome these limitations,
high b-value diffusion imaging was additionally applied
in the abovementioned Shi pup study.87 Results showed
that the zero-displacement probability P0, which is
obtained from high b-value diffusion imaging and which
describes the degree of water restriction in tissue, was
similarly sensitive to the paucity of myelin as the DTI
parameter RD, which is more widely available on clinical
scanners.
Human DTI studies comparing FA, AD, and RD
parameters indicate RD to be the most sensitive in dis-
tinguishing HLD patients from controls (see Fig 2M–P).
A case study of a family with a unique mutation of
PMD has described increases in the lowest eigenvalues,89
and a preliminary study in a larger group of patients
with several HLDs also identified RD as the most rele-
vant DTI parameter (Steenweg et al, unpublished).
Although DTI parameters are indicative of myelin
content, they are sensitive to changes in myelination, and
thus may serve to detect treatment effects. With the
hsv-tk1 mouse model, which has a phenotype with a
transient, reversible hypomyelination,85 strongly elevated
RD was observed at 2 weeks of age, which normalized in
the following weeks with myelination. Another study
performed high-field ex vivo DTI to follow transplanta-
tion of immunodeficient Shi mice with human neural
stem cells (NSCs).90 The study did not determine AD
and RD separately, but an increase of FA was observed
in those areas that also showed myelination on histopa-
thology. A recent human phase I study evaluated safety
and evidence of myelin formation after transplantation of
human CNS stem cells in 4 subjects with an early onset
severe form of PMD.91 DTI showed an increase of FA
and decrease of RD consistent with myelination, in the
region of transplantation compared to control white mat-
ter regions remote to the transplant sites.
Currently, these techniques all have roles in assess-
ing hypomyelination. MRS shows specific findings in
some disorders, but none that is applicable to the entire
group of HLDs; it does not allow myelin quantification.
MTI is quantitative, and its results are clearly associated
with myelin presence, but it is not specific for the bind-
ing of water to myelin and therefore will never be pre-
cisely quantitative for myelin. DTI is very sensitive to
changes in water motion associated with myelination, but
the changes in water motion are not specifically caused
by myelin; therefore, although very characteristic diffu-
sion changes are caused by myelination, observation of
those changes cannot be absolutely interpreted as being
the result of myelin, nor can they be used to quantify
myelin. Diffusion techniques are likely to improve sub-
stantially with technical improvements. MWF, although
currently still limited by lack of spatial coverage, time
requirements, and frequent technical difficulties that
result in artifacts, shows promise for quantitative myelin
analysis with technical improvements.
Emerging Therapies in HLDs
Despite current limitations of MRS, DTI, and MTI in
quantifying myelin, these MRI techniques, or a combina-
tion thereof, will become particularly important when
therapies become available for different HLDs. Because
OPCs are defective in HLDs, and the following consider-
ations, cell-based therapies have emerged as candidates
for therapeutic research. In preclinical studies, biological
properties of OPCs suitable for transplantation include
self-renewal and migration.92 Second, NSCs and OPCs
can engraft successfully in mouse models of hypomyeli-
nation, conferring functional properties of myelin, such
as an enhanced conduction velocity to host axons.90 A
final attribute making HLD a focus of clinical studies is
that MRI might comprise a noninvasive method for
identifying functional engraftment of myelinating cells in
the grossly hypomyelinated background of the host/
patient brain.
For these reasons, a 2007 National Multiple Sclero-
sis Society workshop proposed PMD as a proof of con-
cept disorder for cell-based therapies to restore myelin.93
These considerations promoted a phase I clinical study of
allogeneic NSC transplantation in 4 patients with conna-
tal PMD who were followed clinically and with frequent
MRI.91 These studies showed that the procedure, the
immunosuppression, and the transplanted cells them-
selves were safe 1 year after the transplant. Moreover,
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DTI changes in the region of the transplant showed
increasing FA and decreasing RD, suggestive of engraft-
ment and consistent with the possibility of myelin forma-
tion in those regions. Thus, this study encourages later
(phase II/III) testing to prove efficacy of these approaches
in HLDs.
However, the outcomes of such studies require
expert opinion as to surrogate biomarkers and/or clinical
measures that can be employed in the proof of efficacy.
By definition, ultrarare disorders have no normal baseline
and stereotyped natural history, but rather involve a spec-
trum of outcomes. To enhance the testing of potential
clinical interventions for HLDs, surrogate biomarkers
should be adopted as primary outcomes, with careful
tracking of clinical outcomes as secondary measures. The
following section establishes expert opinion on the cur-
rent knowledge and research of possible endpoints for
clinical trials in HLDs.
Exploring Surrogate Clinical Endpoints for
HLDs
To define clinical endpoints for ultrarare disorders such
as HLDs is challenging. Clinical presentation varies from
one HLD to another, and complexity is also conferred
by individual/developmental changes in the first years of
life. For example, classic PMD patients usually have
intellectual disability and a complex neurological syn-
drome consisting of spasticity, ataxia, and an extrapyra-
midal movement disorder, which is so severe that
walking and even sitting without support are not possi-
ble. In contrast, patients with the other common HLD,
4H, usually learn to walk without support before their
third year of life and have much better cognitive abilities,
their main neurological sign being ataxia.94,95 Even
within a given HLD, the spectrum of severity is wide.
For PMD, there is clear genotype–phenotype correla-
tion96,97; for 4H and other HLDs, this relationship is
less obvious. To make things even more complicated, the
majority of patients with HLD slowly deteriorate after a
period of clinical stability, probably due to axonal degen-
eration, mirrored in the global atrophy seen in longitudi-
nal imaging (Fig 4).98
Observational studies for most HLDs are lacking.
Specifically, there is urgent need to study the utility of
standardized assessment tools such as the Gross Motor
Function Classification System (GMFCS) and dystonia,
dyskinesia, and ataxia scales, as well as the applicability
of tests of cognitive function in a population with severe
motor handicaps. Besides brainstem auditory responses,
which are typically absent in PMD, there is no evidence
that neurophysiologic or biochemical tools could be used
as surrogate outcome markers in HLDs at this point, but
this needs further investigations, especially in newly
described HLDs.
MRI modalities are currently the most promising
surrogate biomarker for clinical trials of HLD, but any
improvement seen in MRI surrogates needs correlation
with measurable clinical improvement. Of note, MRI
modalities that are used as a surrogate biomarker will
have to take into consideration any physiologic differen-
ces between innate myelination and post-therapeutic
remyelination. These may include such considerations as
the maturity of myelin wrapping, the hydrophobicity of
the myelin membranes, and the size of cytoplasmic chan-
nels after myelin wrapping (see Fig 3A). As discussed
below, new approaches to quantify myelination may pro-
vide the best objective evaluation of effect of a therapeu-
tic trial.
Exploring Basic and Translational Research
to Develop Endpoints for HLDs
New Approaches to Augment Capability of MRI
in Myelin Detection in Humans
The sections above have highlighted scientific opportuni-
ties for glial biology and MRI technology to come
FIGURE 4: Global atrophy as shown on longitudinal mag-
netic resonance imaging. (A, B) Axial T2-weighted images of
an 8-year-old hypomyelination, hypodontia, and hypogona-
dotropic hypogonadism patient with a homozygous mis-
sense mutation in POLR3A. (C, D) severe global atrophy is
visible in the same patient at the age of 19 years, mani-
fested both by an increased volume of cerebrospinal fluid
spaces and by a decreased intracranial volume (thicker
skull).
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together in characterization of myelin disorders. As
described above, although MRI techniques do not
directly quantify myelin, semiempirical or empirical pro-
ton MR models may have promise. For example, several
small animal transgenic mouse models exist with hypo-
myelination and hypermyelination that could be used to
“train” MRI methods for greater fidelity. After imaging,
the tissue sample or animal would be analyzed for myelin
quantity (the “myelin score”) by histology, electron
microscopy, and myelin G-ratios (the ratio of axon to
myelin circumference).99 A weighted combination of MR
parameters can be selected that best explain the experi-
mentally determined myelin quantities, a process that
needs iterative validation. It would be essential to also
study animals or samples with inflammatory infiltrates to
ensure that a differentiation could be made based on spe-
cific parameters (for example, FA, MWF, and MT would
be expected to be increased and RD to be decreased with
myelination as compared to inflammation). Others have
developed myelin-specific gadolinium-complexed MR
contrast agents that appear to bind myelin with high
specificity and may become clinically useful if they can
be modified to cross the blood–brain barrier after intra-
venous infusion (current compounds require intraventric-
ular infusion).100 If the compounds bind to myelin in a
consistent manner, quantification would potentially be
obtainable by relaxometry alone. The goal of these stud-
ies would be to refine MRI power to identify myelin
quantity in vivo.
Several centers have adopted the use of positron
emission tomography in clinical studies of multiple scle-
rosis patients. These studies have used11C-labeled N-
methyl-4,40-diaminostilbene101 to demonstrate accumula-
tion of the compound in myelinating structures in devel-
oping animal models, disappearance of the tracer after
autoimmune demyelination, and reappearance after
remyelination.102,103 This compound readily crosses the
blood–brain barrier and appears to be highly specific for
myelinated regions.101 One disadvantage is exposure of
the brain to (relatively low levels of ) radiation.
Finally, in vitro systems of myelination are helping
to define processes that regulate myelin initiation and
wrapping.104 Dual mode imaging incorporating light
and/or fluorescent microscopy with simultaneous MRI is
envisaged as a way that basic glial biology and MR sci-
ence might come together to enhance our capabilities for
sensitive and specific detection of myelin by MRI.
Patient-Specific Models and Potential Therapies
for HLDs
The past decade has seen a revolution in stem cell biol-
ogy that has resulted in new and promising techniques
for investigation of human disease and patient-specific
modeling. Embryonic stem cells (ESCs) are defined by
their capacity for self-renewal and totipotency, and mouse
and human ESCs can be differentiated into oligodendro-
cytelike precursor cells.100,105,106
Findings in the past decade have shattered the
dogma that differentiation is a one-way process; it is pos-
sible to convert fibroblasts back into pluripotent
cells.107,108 Such induced pluripotent stem cells (iPSCs)
can be converted into OPC-like progenitors for studies
of myelin biology in vitro100 and rescue of the Shi mouse
in vivo.109 Direct conversion of fibroblasts into OPC-like
cells, bypassing the iPSC stage, has recently been demon-
strated in rodents.110,111 Thus, many avenues are avail-
able for direct production of OPC-like progenitor cells
derived from patient material for in vitro and in vivo
studies to gain new insights into the nature of pathogenic
mutations and therapeutic approaches in HLDs.
New technologies for site-specific mutations using
TALEN112 and CRISPR113,114 technologies make it fea-
sible to create targeted patient-specific mutations to study
effects on oligodendrocyte biology, such as engineering
patient-specific PLP1 mutations into ESCs to elucidate
their impact on oligodendrocyte maturation, survival,
and myelination. Another exciting opportunity may be
the reversal of patient-specific mutations through gene
correction. Future cell-based therapies for HLDs might
proceed from production of iPSCs, gene correction, pro-
duction of OPCs, and eventual autologous transplanta-
tion. However, use of such applications in the brain is
likely years away because of safety concerns (eg, potential
for oncogenic transformation).
Conclusion
We anticipate that new clinical trials (pharmacological
and cell-based therapies) will be forthcoming in the next
several decades for HLDs. In ultrarare disorders, clinical
trials require biomarker surrogates of efficacy and might
be eligible for US Food and Drug Administration Fast
Track status. MRI is commonly used in diagnosis of all
myelin disorders including HLDs, and is currently the
most promising biomarker. We believe it is of utmost
importance to prepare for these clinical trials with natural
history studies and collection of clinical MRIs. We there-
fore recommend careful and systematic collection of clin-
ical data via consortiums such as GLIA (Global
Leukodystrophy Initiative) and LeukoNet, as well as
standardized minimal clinical MRI sequences, including
at least DTI, MTI, and combined T1 and T2
relaxometry.
Due to the variable clinical presentation of the
HLDs, neurological parameters, which can be used as
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secondary endpoints, are more difficult to define. Reli-
able parameters include GMFCS and the appropriate rat-
ing scales for spasticity, ataxia, and dystonia. Visually
evoked potentials or brainstem auditory evoked potentials
might prove to be other objective and easy to use param-
eters, although they have yet to be validated.
Regarding primary endpoints to be collected in
clinical trials, we recommend the following MRI techni-
ques: conventional imaging, MTI (for MTR and MT sat-
uration), DTI (especially for RD and FA), combined T1
and T2 relaxometry (for MWF), and proton MRS.
Despite the promise of MRI, current individual techni-
ques are not optimized for specific detection of myelin.
We propose a multidisciplinary effort to enhance MRI
sensitivity using new experimental genetic and human-
ized animal systems.
Systematic collection of clinical, electrophysiological,
and MRI data collection in HLDs in natural history stud-
ies will allow us to determine which findings correlate best
with MRI characteristics and could therefore represent
strong secondary endpoints for future therapeutic trials.
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